Delisting Determination, The Nasdaq Stock Market, LLC, July 10, 2026
CERo Therapeutics Holdings, Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove 
from listing the securities of CERo Therapeutics Holdings, Inc. 
effective at the opening of the trading session on July 23, 2026. 
Based on review of information provided by the Company, Nasdaq Staff 
determined that the Company no longer qualified for listing on the 
Exchange pursuant to Listing Rule 5550(b)(1).
The Company was notified of the Staff determination on August 28, 2025. 
On September 3, 2025 the Company exercised its right to appeal 
the Staff determination to the Listing Qualifications Hearings 
Panel (Panel) pursuant to Listing Rule 5815. 
On October 14, 2025, the hearing was held.
On October 28, 2025 the Panel reached a 
decision and a Decision letter was issued on October 29, 2025 
and the Panel decided to suspend the Company from the Exchange.
On October 29, 2025, the Company appealed the Decision of the Panel.
This matter was reviewed by the Nasdaq Listing and Hearing Review
Council (NLHRC).  On January 29, 2025, the NLHRC issued a decision
that upheld the Panel's decision of October 29, 2025. 
The Nasdaq Stock Market LLC (Nasdaq) Board of Directors
did not call for review the January 29, 2026 decision of the NLHRC
and issued a Final Action Letter dated February 6, 2026. 
The Company securities were suspended on October 31, 2025. The 
Staff determination to delist the Company securities 
became final on December 15, 2025.  There was a delay in delisting
because the Company appealed the Panel decision and because of
the previously mentioned procedural steps in this matter.